Vor Biopharma
- Founded: 2016
- Location: Cambridge, MA
- Employee range: 200 - 500
- Clinical stage: Clin1/Clin2
- Therapy area: AML
- Drug types: ONC
- Lead product: Trem-cel
- Product link: https://www.vorbio.com/platform-pipeline/our-pipeline/
- Funding: $116M stock Dec 2022; $203M IPO Feb 2021; $110M B Jul 2020; $42M A Feb 2019
- Investors: Johnson & Johnson Innovation, Novartis Institutes for BioMedical Research, Osage University Partners, PureTech Health
vorbio.com linkedin.com job board
Short description:
CAR-T Stem Cell Therapy
Drug notes:
Also combo Clin0 AML, RD MDS-MPN; VCAR33 Clin1/Clin2 AML, Clin0 post transplant AML; CD33-CLL1 RD AML
Long description:
Vor Biopharma is engineering hematopoietic stem cells (HSCs) to improve the efficacy of treating blood cancers. Current therapeutic strategies for blood cancers involve identifying unique targets on cancer cells. Vor is changing this paradigm by instead engineering healthy cells and making them invisible to targeted therapies. Vor’s approach reduces on-target toxicity of healthy cells by genetically modifying HSCs to remove surface targets expressed by cancer cells. Engineered HSCs are then transplanted back to patients and are then treatment resistant. Vor’s lead product, VOR33, showed promising preclinical data and is now entering clinical trials. The company is also conducting ongoing discovery efforts using their proprietary platform to identify additional surface targets.
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com